Biomedical Research

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 11, 2024

“In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.

Key Points: 
  • “In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.
  • Presented palazestrant monotherapy Phase 2 clinical results at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, as an oral presentation demonstrating compelling activity in both wild-type and ESR1-mutant tumor types.
  • Non-GAAP G&A expenses were $3.1 million and $13.3 million for the quarter and year ended December 31, 2023, respectively, excluding $1.4 million and $5.5 million non-cash stock-based compensation expense respectively.
  • A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Retrieved on: 
Tuesday, February 27, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
  • Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.
  • Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer.

OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors

Retrieved on: 
Tuesday, February 20, 2024

OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.

Key Points: 
  • OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Michael Patane, PhD, to its Board of Directors.
  • "We are thrilled to welcome Dr. Michael Patane to our Board of Directors," said Kurt Riegger, CEO at OcuSciences.
  • “OcuSciences is at a very exciting time in its history as it builds momentum around its novel and patented retinal disease detection modality,” said Dr. Michael Patane.
  • “I am honored to join this Board and look forward to working with my fellow directors and senior management to help OcuSciences advance the development and commercialization of its transformative retinal imaging devices.”

Government of Canada reappoints president of the Social Sciences and Humanities Research Council

Retrieved on: 
Wednesday, February 28, 2024

Through its suite of programs that support research training, insight and partnerships, the Social Sciences and Humanities Research Council of Canada (SSHRC) is playing a key role by promoting collaboration with public, private, not-for-profit and community organizations, as well as with Indigenous peoples.

Key Points: 
  • Through its suite of programs that support research training, insight and partnerships, the Social Sciences and Humanities Research Council of Canada (SSHRC) is playing a key role by promoting collaboration with public, private, not-for-profit and community organizations, as well as with Indigenous peoples.
  • He played an instrumental role in mobilizing social sciences and humanities research expertise to help Canada navigate the pandemic and ensure a strong recovery.
  • "Congratulations to Dr. Hewitt on his reappointment as president of the Social Sciences and Humanities Research Council of Canada.
  • SSHRC is the federal research funding agency that promotes and supports research and training in the humanities and social sciences.

Epicore Biosystems and the U.S. Anti-Doping Agency Partner on an Innovative Collaboration to Deploy Sweat-Sensing Biowearables for Doping Control

Retrieved on: 
Tuesday, February 27, 2024

CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore'), a digital health solutions company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, and the U.S. Anti-Doping Agency (USADA) have partnered to bring Epicore's novel biosensing capabilities to the anti-doping world as a new drug detection method to complement existing urine and blood collections.

Key Points: 
  • The collaboration aims to do just that.
  • To date, athletes have been required to submit blood and/or urine samples for anti-doping efforts, which can be time-consuming and feel invasive for athletes.
  • The Epicore and USADA partnership aims to dramatically improve the status quo by providing a non-invasive, wearable approach to conventional screening using biomarkers and drug detection in sweat.
  • The technology could be especially valuable for in-competition testing to minimize the impact of doping control during a time when athletes face significant demands on their time and bodies.

Western Blotting Market on the Rise, Expected to Hit $2.1 Billion by 2028: Strategic Analysis by BCC Research

Retrieved on: 
Wednesday, February 7, 2024

BOSTON, Feb. 7, 2024 /PRNewswire/ -- Diving into the world of scientific discovery, Western Blotting is like a superhero in the lab, helping researchers unravel the mysteries of proteins in complex mixtures. Picture it as a 'molecular fingerprint' that lets scientists sleuth around, uncovering the who, what, and how many proteins. This technique isn't just a fancy lab trick – it's a powerhouse in understanding diseases, crafting new drugs, and decoding the intricate dance of biological processes. With its fingerprints all over biology, medicine, and biotech, Western Blotting isn't just a tool; it's a key player in the game of life sciences, offering researchers a versatile way to unlock groundbreaking molecular insights.

Key Points: 
  • Embark on a comprehensive journey into the dynamic realm of Western Blotting with our latest report.
  • The journey through time has witnessed transformative modifications, with innovations like multiplex Western Blotting and quantitative techniques enriching its capabilities.
  • Increasing Prevalence of Target Diseases: One of the primary driving forces propelling the Western Blotting market is the escalating prevalence of target diseases.
  • This synergy between government funding and Western Blotting underscores the critical role this method plays in shaping the landscape of biomedical research.

Johnson & Johnson Celebrates Innovation in Novel Drug Delivery Systems with 2023 Dr. Paul Janssen Award

Retrieved on: 
Wednesday, February 7, 2024

NEW BRUNSWICK, N.J., Feb. 7, 2024 /PRNewswire/ -- Johnson & Johnson today announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen Award for Biomedical Research. Dr. Langer was honored for his groundbreaking work in designing novel drug delivery systems that can deliver medications continuously, precisely, and at controlled rates over extended periods. His pioneering research into biomedical compounds for drug delivery has impacts on a wide range of medical technologies, including anticancer therapy, vaccine development, gene therapy and more. 

Key Points: 
  • Dr. Robert Langer to Receive 2023 Dr. Paul Janssen Award for Groundbreaking Research in Biomedical Compounds for Drug Delivery
    NEW BRUNSWICK, N.J., Feb. 7, 2024 /PRNewswire/ -- Johnson & Johnson today announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen Award for Biomedical Research .
  • Dr. Langer was honored for his groundbreaking work in designing novel drug delivery systems that can deliver medications continuously, precisely, and at controlled rates over extended periods.
  • He joins 22 other scientists who have received the Dr. Paul Janssen Award since 2004, including eight who have gone on to win the Nobel Prize.
  • Johnson & Johnson will honor this remarkable scientist during a virtual symposium titled "Pioneering Novel Drug Delivery Systems" at the New York Academy of Sciences on February 8, 2024, from 9:00 a.m. to 12:30 p.m.

Top 5 Innovators to Watch

Retrieved on: 
Tuesday, February 6, 2024

GAITHERSBURG, Md., Feb. 6, 2024 /PRNewswire/ -- Center for Contemporary Sciences (CCS) is announcing the selection of top 5 innovative companies to watch who are at the cutting edge of human biology-based methodologies for drug discovery and development. 

Key Points: 
  • To that end, CCS evaluated more than 150 companies and organizations developing or working with human-relevant technologies for biomedical research and drug development.
  • "I am especially excited to recognize the innovators going the extra mile and educating the public on this technology by including the community recognition criteria," says Public Policy Manager, Mikalah Singer.
  • "We are excited to share this "Top 5 Innovators to Watch" asset with the community to highlight the brilliant work of companies who are focused on human biology-based methodologies," says CEO and Co-Founder, Dr. Aysha Akhtar.
  • Dive into our "Top 5 Innovators to Watch" report to find out who the innovation winners are for human relevant research.

Mainstream American Scientist Bruce E. Rapuano Goes on the Record with His Own UFO Close Encounters and Alien Abduction Experiences in a Newly Released Book

Retrieved on: 
Monday, February 5, 2024

NEW YORK, Feb. 5, 2024 /PRNewswire/ -- A newly published nonfiction book is the only first-person account to date of multiple UFO close encounters and alien abductions authored by a mainstream American scientist.

Key Points: 
  • NEW YORK, Feb. 5, 2024 /PRNewswire/ -- A newly published nonfiction book is the only first-person account to date of multiple UFO close encounters and alien abductions authored by a mainstream American scientist.
  • How the implants that are frequently reported by abductees work to analyze and influence the activity of the human brain.
  • Potentially breakthrough scientific innovations underlying these highly advanced alien capabilities are revealed that make the book a de facto whistleblower report on the subject of UFO's and alien abduction.
  • For more information, visit : Amazon.com: Dominion Lost: A Scientist's Own Alien Abduction Encounters eBook : Rapuano, Bruce: Kindle Store , Amazon.com: DOMINION LOST - Abridged Version: A Scientist's Own Alien Abduction Encounters eBook : Rapuano, Bruce: Books and Facebook (https:// www.facebook.com / profile.php?id = 61553229350298).